key: cord-0806433-3c2eq86e
authors: Fallica, Antonino N.; Pittalà, Valeria; Modica, Maria N.; Salerno, Loredana; Romeo, Giuseppe; Marrazzo, Agostino; Helal, Mohamed A.; Intagliata, Sebastiano
title: Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective
date: 2021-06-02
journal: J Med Chem
DOI: 10.1021/acs.jmedchem.0c02265
sha: a6284339f4db7cdbe945470dc4ed802811d4a9ff
doc_id: 806433
cord_uid: 3c2eq86e

[Image: see text] Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified into two subtypes indicated as σ(1) and σ(2), might play a pivotal role in cancer growth, cell proliferation, and tumor aggressiveness. As a result, the development of selective σR ligands with potential antitumor properties attracted significant attention as an emerging theme in cancer research. This perspective deals with the recent advances of σR ligands as novel cytotoxic agents, covering articles published between 2010 and 2020. An up-to-date description of the medicinal chemistry of selective σ(1)R and σ(2)R ligands with antiproliferative and cytotoxic activities has been provided, including major pharmacophore models and comprehensive structure–activity relationships for each main class of σR ligands.

Cancer is a severe health concern, and it is the second leading cause of death globally. 1 According to a World Health Organization report (2020), the global cancer burden is significant and increasing, with an estimated 9.6 million deaths worldwide from cancer in 2018. About 300,000 new cases per year have been diagnosed among children aged 0−19 years, while the calculated total annual cost of cancer in 2010 was more than US $1 trillion worldwide. Usually, treatment options include chemotherapy, radiotherapy, and surgery. Frequently, the toxicity of large doses of chemotherapy and the lack of effectiveness in certain tumors make surgery and radiotherapy the preferred options. By definition, anticancer drugs target rapidly multiplying cells, leading to variable toxicities to the gastrointestinal tract, bone marrow, hair follicles, and gonads. Hematological toxicity manifests as acute cytopenia due to the cytotoxic effect on the hematopoietic precursor cells. The gastrointestinal toxicity, nausea, vomiting, and anorexia is usually a physiological reflex to remove toxic substances from the gastrointestinal tract. Nausea is a widespread side effect among chemotherapeutic agents and entails 5-HT 3 antagonists such as ondansetron in several situations. Another common toxicity is hair follicle damage which represents both physiological and psychological burdens for the patients. Alopecia usually develops due to the cytotoxic effect of the drug on the rapidly dividing hair follicles. Finally, neurotoxicity can occur with drugs that cross the blood−brain barrier, such as vincristine, 5-fluorouracil, thiotepa, and cisplatin. Some other agents can cause peripheral neuropathy, such as paclitaxel and carboplatin. Besides, several factors may affect the effectiveness of the chemotherapy regimen, including early intracellular drug inactivation, overexpression of drug efflux pumps, low drug uptake, or dysregulation of specific intracellular signaling pathways targeted by the therapeutic drugs. Despite the striking results obtained by tumor immunotherapy and nanomedicine, 2,3 several issues still need to be overcome. These factors emphasize the need to identify and validate alternative biological targets mainly detectable in tumor cells and develop novel anticancer agents with enhanced efficacy, safety profile, and compliance. 4, 5 Sigma receptors (σRs) are considered promising targets for treating different heterogeneous medical conditions, including cancer. 6−8 The history of σRs began in the early 1970s when Martin et al. proposed the involvement of a subtype of the opioid receptor family, named the "σ-opioid" receptors, in the psychotomimetic effects caused by the putative opioid agonist N-allylnormetazocine derivative (±)-SKF-10,047 in the spinal dog model. 9, 10 However, later on, the binding site within this protein, whose gene sequence was cloned by Su and colleagues, 11 was unresponsive to naloxone and naltrexone, suggesting the distinction of this type of protein from opioid receptors. In the following years, SKF-10,047 was found to interact with many biological targets, adding confusion about the classification of σRs. 12, 13 Further studies on this compound determined that it could not be completely displaced from its receptor using selective opioid ligands, indicating that it was bound to another distinct receptor. More specifically, racemic SKF-10,047 has the ability to produce algesia and psychotomimetic effects in humans. The analgesic effect is believed to be mediated through the action of (−)-SKF-10,047 on the μ and k opioid receptors. Conversely, it was found that (+)-SKF-10,047 binds with very low affinity to both opioid receptors, and its pharmacological action is mediated through a different site. 14 This other site has since been designated as the σR. 15 Further studies proved that σRs are a non-opioid, non-GPCR transmembrane protein expressed mainly in the endoplasmic reticulum (ER) membrane and physically associated with the mitochondria. 16 σRs act as chaperone proteins that interfere with ion-channels and GPCR receptors activity modulating several physiological pathways through ER stress and control of intracellular Ca 2+ homeostasis. 17 Ultimately, σRs have been classified into two subtypes, σ 1 and σ 2 receptors, depending on their biological actions, distribution, sizes, and other factors. 8 It was only in 1996 that the gene sequence of σ 1 R has been cloned by Hanner et al. 18 and was found to be expressed in various tissues inside and outside the CNS. The σ 1 R subtype has been cloned from many species, including mice, rats, guinea pigs, and humans. It is a 223 amino acid protein with a molecular weight of about 24 kDa. σ 1 Rs are widely distributed in several tissues, and they are present in the brain, spinal cord, and peripheral nerves. 19 A breakthrough occurred in 2016 with the publication of the three-dimensional (3D) crystal structure of the human σ 1 R by Schmidt and co-workers. 20 The reported structures showed a trimeric architecture formed by the association of three identical protomers possessing a single transmembrane domain ( Figure 1A ). 20 So far, five different crystal structures of the σ 1 R in complex with historical σ 1 R ligands (i.e., (+)-pentazocine, haloperidol, NE-100, PD144418, and 4-IBP) have been reported, 20, 21 which have revealed a preserved ligand's binding mode with high similarity shared by different chemical classes. Notably, the ligand-binding site is deeply located inside the large β-barrel region where ligands are accommodated in a very hydrophobic pocket entirely occluded from solvent molecules.

Analysis of the protein−ligand contacts outlines a major ionic bond involving the basic nitrogen of the σ 1 R ligand (e.g., PD144418, Figure 1B ) and the Glu172 amino acid residue as well as multiple hydrophobic interactions with bulky hydrophobic residues (i.e., Val84, Trp89, Met93, Tyr103) that shape the internal edge of the binding pocket.

Growing evidence implicates the σ 1 R in various neurological disorders such as depression, anxiety, schizophrenia, and Alzheimer's disease. 22 Recent studies suggest that σ 1 R modulators possess the therapeutic potential to treat drug abuse. 23 Interestingly, recent studies have investigated the repurposing of σ 1 R ligands for interfering with the early stages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. This approach was inspired by the colocalization of σ 1 R with the viral replicase protein in the ER membrane and its interaction with the nonstructural SARS-CoV-2 protein Nsp6. 24, 25 Nowadays, the oncogenic role of σ 1 Rs has not been fully elucidated. It is known that this protein is overexpressed in a wide number of cancer cell lines and σ 1 Rs fully functional activity is required for proper growth, proliferation, migration, and survival of cancer cells. The use of σ 1 R negative modulators, often considered as "σ 1 R antagonists", or σ 1 gene silencing through the application of RNAi hamper tumor cell growth and survival. 6 Contrarily, the overexpression of σ 1 Rs through recombinant techniques or the σ 1 Rs positive modulation exerted by selective small molecules, often considered as "σ 1 R agonists", causes opposite effects. 6 Unlike the σ 1 R, up to now, the crystal structure of the σ 2 R is still unknown. The difficulty of its isolation and purification is mainly due to its distribution in the lipid environment and its low abundance in the prepared mammalian membranes. 12 The genetic identity of the σ 2 R was revealed recently in 2017 when Alon et al. used classical affinity purification approaches to isolate the σ 2 R binding site and characterized it as the (ER)resident membrane protein, transmembrane protein 97 (TMEM97), with a molecular weight of about 18−21.5 kDa (frequently referred to as σ 2 R/TMEM97). 26 In 2011, Xu and co-workers reported that progesterone membrane binding component-1 (PGRMC1) could bind to σ 2 R, altering the pharmacological properties of its ligands. 27 More recently Mach and collaborators from the University of Pennsylvania, using a gene-editing approach, demonstrated that TMEM97 and PGRMC1 could form a ternary complex with the low density lipoprotein (LDL) receptor leading to a muchincreased LDL internalization. 28 This observation, confirmed by confocal microscopy and radioligand binding studies, indicated the involvement of σ 2 R/TMEM97 in lipoprotein trafficking and could rationalize the upregulation of σ 2 Rs in certain types of cancer cells. 45 The recent discovery of the identity of the σ 2 R rationalizes the search for small molecules with potential neuroprotective, 29 antinociceptive, 30 and antiproliferative effects. 31 Concerning the role of σ 2 Rs in the context of cancer, different pharmacological studies have proved that the σ 2 R is overexpressed in cancer cells, and its abundance is correlated with the proliferative status of certain tumors. 32 Furthermore, in addition to the diagnostic imaging application, σ 2 R ligands have shown cytotoxic effects in tumor cells in vitro and in vivo. 33−36 A better elucidation of the implication of σ 2 Rs in tumor cell death was reported in 2019 by Zeng and coworkers, which conducted CRISPR/Cas9 studies to assess the cytotoxic properties of σ 2 R ligands in TMEM97 knockout (KO), PGRMC1 KO, or TMEM97/PGRMC1 double KO cell lines. 37 Results showed that induction of cell death by σ 2 R ligands was not hampered, suggesting that the cytotoxic effects are not directly mediated by TMEM97 or PGRMC1, thus questioning the exact cytotoxic mechanism exerted by σ 2 R ligands.

Following the differentiation of the two σR subtypes, tremendous efforts were directed toward developing selective ligands for each subtype. (+)-Pentazocine (Figure 2 ), the first σ 1 R selective ligand, exhibited 500-fold selectivity (σ 2 K i /σ 1 K i ) over the σ 2 R receptor. 38 Also, the 1,2,4-triazole derivative E-5842 ( Figure 2 ) showed a K i value of 4 nM for the σ 1 R and 55fold selectivity. 39 Later, a dipropylamine derivative named NE-100 ( Figure 2 ) was reported to have a high affinity for the σ 1 R and moderate selectivity over the σ 2 R. 40 Haloperidol ( Figure  2 ) is a butyrophenone derivative belonging to the drug class of neuroleptics, mainly acting as a D 2 antagonist. For many years, haloperidol has been used as a reference σ 1 R antagonist, and it represents a classic σR ligand prototype. Its antagonist profile toward the σ 1 R was discovered more than 20 years ago, along with its in vitro and in vivo anticancer properties toward several cancer types. 41−47 In 2011, Schlager et al. reported a series of spirocyclic pyranopyrazoles with high σ 1 R affinity and selectivity toward the σ 2 R, α 1 , α 2 , 5-HT 1A R, and the 5-HTtransporter. 48 Two chemically and pharmacologically distinct high-affinity σ 1 R ligands named 4-IBP (agonist or inverse agonist) and PD144418 (antagonist) were used to obtain the above-mentioned first crystal structures of the human σ 1 R ( Figure 2 ). 49, 50 Compound CB-184 ( Figure 2 ) was the first reported highly selective σ 2 R ligand back in 1995 by Bowen and co-workers. 51 This compound was followed by several other σ 2 R ligands belonging to diverse chemical classes (discussed in more detail in Section 3.2), including the indole alkaloid ibogaine 52,53 and the granatane derivative WC-59. 54 Most of the reported σ 2 R ligands discovered to date were developed for their cytotoxicity properties toward several cancer cell lines; 43 however, the most recently reported methanobenzazocine derivative UKH-1114 55 and the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative CM398 56 ( Figure 2 ) showed an exquisite σ 2 R selectivity and demonstrated to produce antinociceptive effects in vivo.

To date, a few σR ligands have entered clinical trials to treat different diseases, including neurodegenerative diseases, mental disorders, and pain management. Among them, MR309 ( Figure 3 ) has been the first selective σ 1 R antagonist to reach phase II clinical trials for the treatment of oxaliplatininduced neuropathic pain, and it represents a potential first-inclass analgesic. The randomized, double-blind, placebocontrolled study started in patients with colorectal cancer receiving FOLFOX, aimed to assess the efficacy of MR309 in ameliorating oxaliplatin-induced peripheral neuropathy (OX-AIPN). Interestingly, discontinuous MR309 administration resulted in a potential neuroprotective role for chronic cumulative OXAIPN, with a reasonable safety profile. 57 The radio-tracer [ 18 F]FTC-146 ( Figure 3) , which is the most selective σ 1 R ligand known to date (>146,000-fold selectivity over the σ 2 R and >10,000-fold selectivity over 59 different targets), is currently in phase I clinical trials as a firstin-class diagnostic agent for positron emission tomography− magnetic resonance imaging (PET−MRI) to detect sites of nerve damage in patients with neuropathic pain. 58 The nonradiolabeled analog, named CM304 and acting as σ 1 R antagonist, showed a low pharmacokinetic profile with a short in vivo half-life (115 min) and undesirable clearance (Cl = 33 mL/min/kg) 59,60 which did not allow the compound to move into clinical research, even though it showed efficacy in multiple preclinical mice models of pain. 61, 62 The tetrahydrofuran derivative ANAVEX2-73 ( Figure 3 ), acting as a mixed muscarinic receptor/σ 1 R ligand, is currently in phase II clinical evaluation to treat patients with mild to moderate Alzheimer's disease. 63 Similarly, T-817MA, a highaffinity σ 1 R agonist with neuroprotective properties in rats, 64 reached phase II clinic studies for the same medical condition, while cutamesine ( Figure 3 ), another selective σ 1 R agonist, 65 has been evaluated in phase II studies in patients for recovery enhancement after acute ischemic stroke. 66 Concerning clinical candidates targeting the σ 2 R subtype, two different antagonists, roluperidone and CT1812 ( Figure  3 ), entered phase II and phase I clinical trials to establish their efficacy and safety in the treatment of schizophrenia and Alzheimer's disease, respectively. 67, 68 Interestingly, none of the σR ligands with intrinsic cytotoxicity properties discovered so far are in clinical trials to treat cancer, likely due to the inconsistent data concerning the efficacy of σRs ligands on preclinical in vivo models. This situation was aggravated by the unavailability of the genetic data of the σ 2 R subtype until its cloning in 2017. Usually, full characterization of the molecular target is required to link the chemical probe-target engagement to the functional pharmacology before launching a full drug discovery program. Indeed, the precise role of σRs in cancer biology has not yet been entirely clarified. However, the involvement of σRs in the induction or inhibition of apoptosis, cell growth, proliferation, and tumor progression paved the way for developing small molecules that could be exploited in novel anticancer therapies. The cytotoxic or antiproliferative properties of σR modulators are exerted by interfering with both σ 1 and σ 2 receptors. In particular, inhibition of the σ 1 R or induction of the σ 2 R activities seems to lead to tumor growth inhibition. 69 Specifically, it has been observed that σ 1 R negative modulators cause a caspase-dependent induction of apoptosis, whereas σ 2 R positive modulators mediate a caspaseindependent induction of programmed cell death, 70−72 even though this aspect could not be considered as a rule of thumb because of some exceptions. Generally, a reliable in vitro protocol useful to distinguish between the agonist or antagonist properties of σ 1 R and σ 2 R ligands has not been established yet, mostly due to a lack of known endogenous ligands which does not allow to compare the molecular effect of a tested compound at the level of the receptor. Despite this fact, the apoptotic mechanism of induction employed by σR modulators has been previously used as a judgment parameter to establish the functional activity of σ 2 R ligands, as described by Zeng et al. in 2014. 73 However, based on the recent finding reported from the same research group, nowadays it is known that this approach of σR ligands characterization is not suitable. 37 Nevertheless, the selective overexpression of σR in cancer cells makes it an attractive target for developing useful diagnostic agents, such as the σ 2 R molecular probe named 18 F-ISO-1 (Figure 3 ), that has been assessed in clinical trials to evaluate the safety and feasibility of imaging tumor proliferation by PET in patients with diagnosed malignant tumors. 74, 75 Regarding this aspect, several comprehensive review articles dealing with the development of σR radiotracers to diagnose cancer have been recently published; 76−78 thus, we will not discuss this further. Alternatively, discovering novel anticancer agents that can potentially treat certain tumors with a more selective cytotoxic profile would significantly advance global health.

Based on these premises, this perspective highlights state of the art development of σR ligands with potential anticancer activity, mainly covering articles published between 2010 and 2020. In particular, in this work, the literature search has been conducted using SciFinder and PubMed online databases and choosing "sigma receptors, sigma-1 ligands, sigma-2 ligands, cancer, cytotoxicity, anticancer agents" as keywords. After a cross-match searching process, only significant research articles strictly related to this perspective's topics have been selected. First, we will briefly overview the most significant σR pharmacophore models reported to date to provide detailed information about essential chemical features required for ligands binding at σRs. Second, the most recently reported σR ligands with antiproliferative and cytotoxic activities will be covered, particularly selective σ 1 R and σ 2 R ligands. Extensive structure−affinity relationships (SAfiRs) and structure−activity relationships (SARs) regarding the main classes of σR ligands will be discussed and summarized in each section. Finally, a comprehensive medicinal chemistry perspective on the past, present, and future of σR ligands as a new potential generation of cytotoxic agents will be provided.

There is a large number of reported σR ligands in literature with no clear SAfiRs or SARs. As mentioned earlier, the crystal structure of σ 1 R was released in 2016. Also, the 3D structure of σ 2 R is not yet available for structure-based design. Hence, most of the rational 57,79 design attempts of σR ligands were ligandbased modeling. The main issue that hindered the development of pharmacophore models for σRs is the structural diversity of the reported ligands. The first model was reported by Gilligan et al. in 1992 with four pharmacophore elements for σ 1 R binding, namely, a basic nitrogen atom, two hydrophobic groups, and an H-bonding center midway between the basic N and the distal hydrophobic site ( Figure  4A ). 80 It is worth noting that this first model was not ideal for database mining since it only explained the binding characteristic of one class of compounds.

Following that early attempt by Gilligan, several ligandbased models for σ 1 R or σ 2 R ligands have been reported. These models and their applications will be discussed in the following section. The second prominent attempt was reported by Glennon and co-workers in 1998. They developed a comparative molecular field analysis (CoMFA) model based on the binding data of 64 benzonorbornane derivatives to σ 1 R. The model showed a good correlation coefficient (R 2 = 0.989) and predictive ability (Q 2 = 0.732) and supported the proposal of Gilligan. The Glennon model comprises a central basic nitrogen flanked by two hydrophobic/aromatic moieties, one of them is significantly larger than the other ( Figure 4B ). Also, the hydrophobic groups are not located at equal distances from the basic core. The smaller is 2.5−3.9 Å, while the larger group is proposed to be 6−10 Å away from the basic nitrogen ( Figure  4B ). One of the early trials to address the diversity of σ 1 R ligands in the developed pharmacophore was reported by Jung and co-workers in 2004. This model includes two aromatic rings, a carbon centroid, the basic nitrogen, and a hydrogen bond close to the basic nitrogen (not shown). In 2009, Glennon reported a CoMFA model for σ 2 R based on a series of cyclohexylpiperazines. This model showed a similar arrangement to previously reported σ 1 R models with a correlation coefficient of 0.95 and a cross-validated one of 0.73. 81 Vio et al. used Catalyst software and the HypoGen algorithm to prepare a common-feature pharmacophore for a series of benzo[d]oxazolone with high affinity to the σ 1 R. 82 Although the model was based on different compound series, it was in perfect agreement with Glennon's previous model with very similar distances and features, including two aromatic rings (HYAr), one hydrophobic (HY), one hydrogen-bond-acceptor group (HBA), and one positive ionizable (PI) feature ( Figure  5A ).

The same research group has also reported another pharmacophore model for σ 2 R ligands based on benzo[d]oxazolone derivatives ( Figure 6A ). 84 The latter exhibited a very similar arrangement to that of the σ 1 R previously developed by the same group and the one developed by Glennon. Nevertheless, compared to Glennon's pharmacophore, the distance between the primary hydrophobic region and the basic nitrogen is significantly shorter (4.96 Å). 84 In 2012, Meyer et al. reported a σ 1 R ligands pharmacophore based on a novel series of spirocyclic thiophenes also using the Catalyst software ( Figure 5B ). 83 This model is comprised of the same five features described by Vio et al. with the positive ionizable feature located 4.36 and 9.77 Å away from the two hydrophobic features. Recently, in 2019, scientists from the ESTEVE pharmaceutical company developed a σ 1 R pharmacophore based on the published crystal structure (PDB ID: 5HK1) of the receptor ( Figure 5C ). 85 This model was compared to the previously mentioned pharmacophores and has been validated using a large database of 25,000 compounds with known σ 1 R affinity. Researchers have used the receptor− ligand pharmacophore generator job implemented in the Discovery Studio software which identifies all the critical ligand−protein interactions and then places exclusion volumes to account for any steric considerations. This model identified Glu172 as the positive ionizable group site while placing the two hydrophobic features within the space defined by residues Tyr103, Leu105, Leu95, Tyr206, Leu182, and Ala185 and confined by helices α4 and α5. This ESTEVE pharmacophore outperformed previously published models and, according to the authors, showed better results than molecular docking. On the other hand, the most recent σ 2 R ligands pharmacophore was published in 2019 by scientists from Northwestern University. 86 They developed a series of tetrahydroindazoles and used the obtained SAR data to build the model using the PHASE module as implemented in the Schrodinger software suite. This pharmacophore model consists of one PI group, one HYAr ring, and three HY moieties ( Figure 6B ). Although the distances were not reported, the arrangement showed an equal disposition between the basic nitrogen and two hydrophobic groups.

Generally speaking, the development of σ 1 R ligands depended mainly on ligand-based design, especially on the general pharmacophoric features suggested by Glennon and co-workers. 87, 88 Despite the availability of the σ 1 R crystal structure since 2016, several studies still depend on the general sigma pharmacophore for the design of novel ligands. This approach has been successful and led to the discovery of several high affinity ligands. 82, 85, 89 Moreover, some of the reported pharmacophore models addressed the σR subtype selectivity and highlighted the feature required for binding at each subtype. However, to date, we believe that selectivity against other CNS receptors has not been adequately addressed using ligand-based design methods. Noteworthy, Greenfield et al. recently provided a good example of a highthroughput structure-based computational docking approach as an effective method for the discovery of new selective σ 1 R ligands (Figure 7 ). 90 The platform has been developed performing an iterative process of molecular docking experiments with increased precision levels through screening a library of 6 million compounds.

It should be emphasized that most of the known σR ligands possess heterogeneous structures and can adopt several binding conformations targeting any of the σR subtypes. Developing a 3D QSAR model covering diverse ligands adapting various binding modes is challenging. Also, the binding site of the crystallized σ 1 R is flexible, elongated, and can bind large diverse molecules. 20, 21 Docking into such flexible sites is difficult and could give a high percentage of "false positives". Therefore, we generally recommend using a combined ligand-based (pharmacophore or QSAR) and structure-based (homology modeling and docking) approach. A combination of drug design methods should better predict the activity and eliminate more of the "false positives". 91 3. σR LIGANDS WITH CYTOTOXIC EFFECTS 3.1. Selective σ 1 R Ligands. Over the years, several selective σ 1 R ligands whose antiproliferative properties have been corroborated by several studies have been reported. Rimcazole binds to σRs, serotonin transporter, and with higher affinity to the dopamine transporter. 92 It was initially evaluated for the treatment of schizophrenia and later for its anticancer activity. Specifically, the antiproliferative effects exerted by rimcazole are counterbalanced by the σ 1 R agonist (+)-SKF-10047; thus, rimcazole has been classified as a putative σ 1 R antagonist. 69 Moreover, rimcazole demonstrated to inhibit cell proliferation on xenografted models of hormonesensitive and insensitive breast cancer cell lines. 70, 93 Particularly, completion of its anticancer activity seems to require the HIF-1α induction (mediator of apoptosis) 94 or the presence of the p53 protein. 69 Despite these preclinical results, rimcazole was never fully considered a potential candidate for anticancer therapy because of its off-target effects related to the interference with dopamine neurotransmission. IPAG, initially synthesized as a possible radiotracer, is a potent tumor suppressor and autophagy inducer. 95 Also, its ability to induce an unfolded protein response has been reported in several carcinomas, including pancreas and prostate cancers. 95 SR31747A is a selective σ 1 R antagonist whose antiproliferative activity is associated with immune-modulatory effects in different cancer cell lines with tumor growth inhibition values ranging from 40% to 60% based on the tumor cell lines tested. 96, 97 Finally, the arylalkylethylenediamines BD1047 and BD1063 represent two putative σ 1 R antagonists devoid of cytotoxic properties, although they can induce an altered cell morphology. In general, BD1047 has shown better antitumor effects when compared to its piperazine derivative BD1063. 70, 10 3.1.1. N,N-Dialkyl and N-Alkyl-N-aralkyl Fenpropimorph Derivatives. Despite its amino acid sequence similarity with the yeast C8−C7 isomerase, in 1996, the Glossman research group proved that σ 1 R is devoid of any sterol isomerase activity. 18 Later, the same team found that fenpropimorph (an agricultural fungicide whose mechanism of action implies disruption of ergosterol biosynthesis pathways) had a high affinity for σ 1 Rs (Figure 9 ). In 2007, Ramachandran and colleagues purified a recombinant guinea pig σ 1 R and identified two regions, named steroid binding domain-like I and steroid binding domain-like II, that can serve as additional σ 1 R binding sites. 98−100 Interestingly, these regions share a high similarity with that of the sterol binding domains of the yeast sterol C8− Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective C7 isomerase. The fenpropimorph's chemical structure consists of an aryl ring linked through an alkyl spacer to a nitrogen atom incorporated in a morpholine ring. Considering that the pharmacophore of σ 1 R ligands and the chemical scaffold of fenpropimorph are superimposable, in 2010, Hajipour and co-workers reported the synthesis of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as σR ligands with cytotoxic properties. 101 Among all the tested compounds, 1−3 and 5 exhibited high affinity for the σ 1 R subtype with K i values in the nanomolar range. On the contrary, compounds 4 and 6 displayed a slight preference for the σ 2 R subtype ( Figure 9 ), even with σ 2 K i values in the high nanomolar or micromolar range. SARs were defined for this series of compounds. In general, compounds with a nitro substituent on the phenyl ring were more potent than the corresponding fluorinated derivatives. Compound 1 was about 59-fold more potent than compound 2, whereas compound 5 was 400-fold more potent than its fluorinated analog 4. The authors suggested that the electronwithdrawing properties of the nitro group presumably enhanced the binding with the σ 1 R. Interestingly, when a fluorine atom is present (e.g., compound 4), the binding properties changed in favor of the σ 2 R subtype. The authors also reported the importance of the free lone pair of the nitrogen atom on the alkyl chain, which was necessary for the binding with the σ 1 R, according to Glennon et al. 102 Indeed, the amide derivative of compounds 2 (not shown) did not have any affinity for the σ 1 R. Compounds 1−6 were tested for their cytotoxic properties against a broad panel of tumor cell lines (Table 1) .

Compound 1 showed activity against NCI-H460, SKOV-3, DU145, MCF7, and MB-MDA-231 cancer cell lines. On the other hand, compound 2, which differs from 1 only for the fluorine atom, was active only against SKOV-3 with an IC 50 value of 56.18 μM. Compound 5 demonstrated moderate activity against the MCF7 cancer cell line with an IC 50 value of 88.1 μM. Interestingly, an opposite trend was observed for compound 4, the fluorine derivative of 5. In fact, the former was found to be active on NCI-H460, SKOV-3, MCF7, and MB-MDA-231 tumor cell lines. The better affinity of compound 4 for the σ 2 R subtype with respect to the σ 1 R seems to explain this behavior. Indeed, the σ 2 R subtype is overexpressed in different cancer cell lines, and the authors, at the time of the publication, were not able to explain if the cytotoxic activity was due only to the involvement of the σ 2 R or both receptors. Compound 3 showed to be devoid of any cytotoxic activity in all the tested cell lines. Finally, compound 6 showed no specific cytotoxicity in all the selected cancer cell lines, except for SKOV-3.

3.1.2. Spirocyclic Piperidine Derivatives. 3.1.2.1. Spipethiane Derivatives. In 2010, Piergentili et al. discovered novel highly potent and cytotoxic σ 1 R ligands with a putative antagonistic profile whose chemical structure was based on the spipethiane scaffold (σ 1 pK i = 9.23, σ 2 pK i = 6.40, Figure 8 ), 103 a spiro compound identified as a σR ligand by the same research group in 1998. Bioisosteric substitutions of the sulfur in position 1 and the methylene group in position 3 of spipethiane were performed to expand the SARs of this class of compounds (general structure A, compounds 7−11, Figure  10 ). In addition, a smaller second set of compounds was obtained by deleting the spiro carbon and separating the two hydrophobic portions of the molecule through a carbon− carbon single bond (general structure B, compounds 12−15, Figure 10 ). Moreover, insertion of a carbonyl function in position 4 and homologation at the nitrogen atom of the piperidine ring was also considered. Based on σ 1 and σ 2 radioligand binding assays performed, respectively, on Jurkat cells and rat cerebral cortex membranes using [ 3 H]pentazocine and [ 3 H]1,3-di(2-tolyl)guanidine ([ 3 H]DTG) as labels, SARs were built up. Almost all the novel compounds of the two series had higher σ 1 R affinity values than the lead spipethiane. Bioisosteric substitution of the sulfur atom with oxygen or with a methylene group did not alter the σ 1 R affinity even if a slight increase of affinity was considerable for the σ 2 R (compounds 7−8) with a consequent decrease of σ 1 K i /σ 2 K i selectivity ratio (calculated as the antilogarithm of the difference between pK i at σ 1 and σ 2 receptors). Better results were obtained with compounds 9 and 10, where the methylene group of spipethiane in position 3 was substituted with an oxygen atom. Interestingly, replacement of the methylene group in position 4 with a ketone functional group afforded the best compounds in terms of σ 1 R affinity. The best result was obtained with compound 14, also characterized by the absence of the spiro carbon that links the thiochromane ring to the benzylpiperidine moiety. This compound possessed a σ 1 pK i of 10.28 (σ 1 K i /σ 2 K i = 29,512), and it represented the best σ 1 R ligand reported in the literature at the time of the publication. The high affinity of 14 was explained by hypothesizing that its more flexible structure allowed better interactions with the σ 1 R binding site. However, an increase in flexibility is not always a rule of thumb to be applied to develop selective σ 1 R antagonists. Indeed, compound 15, which is the compound 13 homologous at the nitrogen atom of the piperazine ring, had a lower σ 1 pK i = 9.96 and a σ 2 pK i = 8.08. Therefore, it seemed that the elongation of the alkyl chain in this class of compounds ameliorated the σ 2 R affinity and caused a drastic loss of σ 1 K i /σ 2 K i selectivity ratio.

The spipethiane derivatives 7−15 were tested on MCF-7 and MCF-7/ADR cancer cell lines to evaluate their antitumor properties. The two cancer cell lines were chosen on the basis of their differential expression of σRs; in particular, the high overexpression of σ 1 R subtype characterizes the latter. 104 The authors proved that all the novel compounds possessed cytostatic properties in the MCF-7/ADR cancer cell line with the best GI 50 values obtained with compounds 11 and 13 (10.0 μM and 7.7 μM, respectively), whereas no growth inhibition was observed in the MCF-7 cancer cell line. Also, an analysis of the ability to interfere with the cell cycle by comparing the spipethiane and compounds 13 and 14, which possessed the best σ 1 K i /σ 2 K i selectivity ratio, was made. Specifically, compounds 13 and 14 increased the number of cells in the G 0 /G 1 phase and decreased the number of cells in the S phase in the MCF-7/ADR cell line; the same trend was not observed in MCF-7 breast cancer cells. Contrariwise, spipethiane was not able to affect the cell cycle. The capability of compounds 13 and 14 to induce apoptosis was also described. Indeed, MCF-7 and MCF-7/ADR cancer cell lines were stained with annexin V-FITC to evaluate the expression of phosphatidylserine on the outer layer of the cell membrane, which represents a typical feature of cells in apoptosis. Flow cytometry analysis highlighted phosphatidylserine expression only in MCF-7/ADR cells treated with compounds 13 and 14. Finally, the functional activity of compound 14 was validated using the tail-flick assay. σ 1 Rs are highly expressed in the dorsal horn of the spinal cord, 105 and it has been demonstrated that they can modulate opioid analgesia. 106 In addition, KO of the σ 1 R gene (SIGMAR1) determines pain-attenuated phenotype in mice, supporting the modulatory role of σ 1 Rs in different types of pain (e.g., neuropathic, inflammatory, visceral). 107 Therefore, σ 1 R ligands mimicking this condition are considered putative σ 1 R antagonists or negative modulators. Treatment of CD-1 mice only with 14 did not induce any analgesic effect, whereas pretreatment with morphine and subsequent administration of 14 enhanced the analgesic effect of morphine itself. Altogether, these results were consistent with previously reported findings on σ 1 R antagonist (i.e., BD1047) 106 and proved the putative σ 1 R antagonist profile of compound 14. In our opinion, the combination of structural elements, σRs binding profile, and intrinsic activity makes spipethiane derivatives an exciting class of compounds that might be further developed as cytotoxic agents helpful in those cancer cell lines whose aggressiveness is related to the overexpression of σ 1 Rs.

Derivatives. In the search for selective σ 1 R ligands, molecules with a spirocyclic piperidine scaffold gained much attention over the last decades. With this in mind, the synthesis of spirotetralins, spiro-joined benzofuran, isobenzofuran, and benzopyran piperidine derivatives were described, along with their affinities toward the two σR subtypes. 108−110 Bioisosteric substitution of the benzene ring of spiro-joined benzofuran and benzopyran piperidine derivatives with a thiophene ring gave highly potent and selective σ 1 R ligands. Compounds 16−21 were identified as the most interesting compounds belonging to this series ( Figure 11 ). The main differences between these spiro-piperidines are (i) the presence of an aryl moiety linked to the α-position of the thiophene ring; (ii) the size of the oxygenated ring; and (iii) the nature of the substituent linked to such ring. Among the non-arylated lactones, a thieno[3,4c]furan-3-one scaffold (16) showed the best results in terms of c]pyran moiety led to compounds whose σ 1 R affinity is from 17-to 500-fold higher than those of the parent compound 17. 83 On the contrary, α-arylation of compound 18 (on the same side of the acetalic function) and α-arylation of compound 19 were tolerated. For derivatives of compound 18, both electron-rich and electron-poor phenyl rings as well as naphthyl rings were tolerated. However, a bulky biphenyl moiety was not tolerated. Interesting results have been obtained by insertion of a p-cyanophenyl substituent on the thiophene ring of compound 18. This derivative (compound 20) displayed a σ 1 K i value of 0.25 nM, which is perfectly comparable with the σ 1 K i value obtained for compound 18 (0.22 nM). Meyer et al., who designed and synthesized these molecules, explained this aspect by a possible interaction of the additional aryl moiety with a hydrophobic pocket within the σ 1 R protein that is not accessible for the non-arylated parent compounds. In light of the σ 1 R values, it is clear that the spirocyclic scaffold was responsible for the high affinity for the σ 1 R. In contrast, the aryl moiety allows only additional hydrophobic interactions useful for better binding with the receptor. 111 Aryl derivatives of 19 only tolerated unsubstituted or electron-poor aryl substituents (21, σ 1 K i = 16 nM). 112 In order to establish the selectivity over other receptors, the affinities of compounds 16−21 toward the phencyclidine binding site and the ifenprodil binding site of the NMDA receptor (GluN2B) were assessed. Results showed affinity values exceeding 500 nM and selectivity for the σ 1 R, except for compound 20, which displayed a K i = 91 nM for the GluN2B. 113 Recently, pharmacological characterization of compounds 16−21 has been performed. 113 Non-arylated compounds 16−19 did not display affinities for the serotoninergic 5-HT 1A receptor, the adrenergic α 1A and α 2A receptors, and the serotonin transporter (SERT). Compounds 16, 20, and 21 displayed a negligible affinity for opioid receptors, whereas compound 18 showed a moderate affinity for κ-opioid receptor (KOR) and δ-opioid receptor (DOR). The σ 1 R functional activity of spirocyclic piperidines 16−21 was investigated by merging the information acquired from these compounds' effect on the induced Ca 2+ influx mediated by voltage-gated channels in retinal ganglion cells and the capsaicin assay. In the first test, a non-arylated and an arylated compounds (18 and 20) were used. The KCl-induced Ca 2+ influx through the L-type voltage-regulated Ca 2+ channel was inhibited in the presence of a σ 1 R agonist. On the contrary, σ 1 R antagonists had the opposite effect. Both compounds did not inhibit the KCl-induced Ca 2+ influx, whereas they could reverse the inhibition mediated by the σ 1 R agonist opipramol, suggesting a σ 1 R antagonist profile. The putative σ 1 R antagonist properties were further confirmed with an in vivo capsaicin assay, in which compounds 18, 19, and 21 exhibited antiallodynic effects and a prolonged response latency after mechanical stimulation of the right hind paw of mice previously injected with capsaicin. The antiproliferative properties of these compounds were studied in A427 (nonsmall-cell lung cancer), LCLC-103H (large-cell lung cancer), 5637 (bladder cancer), and DAN-G (pancreatic cancer) cell lines with an in vitro crystal violet staining assay. The A427 and 5637 cancer cell lines were the most sensitive to spirocyclic compounds 16−20. Spiropiperidines 20 and 21 were the most potent toward the A427 cell line, with IC 50 values of 2.6 μM and 5.9 μM, respectively. Considering that the IC 50 values obtained for the A427 cell line were similar to those obtained with the σ 1 R antagonist haloperidol, the authors assumed that the antiproliferative effect of these compounds was mediated by interference with the activity of σ 1 Rs. In addition, the antiproliferative properties of 20 were partially reversed when the σ 1 R agonist (+)-pentazocine was added. By contrast, results obtained in the bladder cell line (IC 50 = 5.5 μM and 9.1 μM for 20 and 21, respectively) The ethylenediamine moiety has been proven to represent a sufficient chemical substructure that allows a high affinity for the σRs. Indeed, almost 30 years ago, it was discovered that the cis-isomers of U50,488 (compound (±)-22, Figure 12 ), a selective KOR agonist, possessed a moderate affinity for the σ 1 R. 115 Reduction of the amide functional group led to the enantiomeric cyclohexandiamine derivatives of U50,488 (compound (±)-23, Figure 12 ), both containing the ethylenediamine moiety and with high affinity for the σ 1 R. 116 Removal of the cyclohexane ring afforded the ethylenediamine 24 ( Figure 12 ) with σ 1 K i and σ 2 K i of 2.1 nM and 8.1 nM, respectively. 117 Compound 24 was used as the lead compound for the discovery of novel σR ligands. 118, 119 To expand the SARs of this class of compounds, the ethylenediamine moiety has been included in a conformationally restricted structure, such as the piperazine ring. Specifically, piperazine derivatives were substituted at both nitrogen atoms with hydrophobic substituents to establish a proper binding with the σR protein. 120, 121 The general structure of these compounds is depicted in Figure 13 . Among the synthesized compounds, a pmethoxybenzyl moiety and a benzyl moiety (compound 25, Figure 13 ) led to a σ 1 K i value of 0.47 nM. In 2004 and 2012, the discovery of chiral and flexible (piperazin-2-yl)alkanol derivatives with a good affinity toward the σ 1 R was reported (general structure in Figure 13 ). 122, 123 The best compounds possessed once again a p-methoxybenzyl moiety and a benzyl moiety linked to the piperazine nitrogen atoms. The methanol side chain (compound 26, Figure 13 ) afforded the best results in terms of σ 1 R affinity (σ 1 K i = 12.4 nM), whereas the ethanol side chain (compound 27, Figure 13 ) afforded a slightly reduced σ 1 K i value (20 nM vs 12.4 nM) but a higher selectivity ratio (σ 2 K i /σ 1 K i > 50). On the other hand, the side chain elongation to three carbon atoms (compound 28, Figure 13 ) caused a considerable reduction of affinity (σ 1 K i = 188 nM).

With the purpose of defining a 3D pharmacophore model that takes into consideration the appropriate spatial orientation of the pharmacophoric elements of a σ 1 R ligand, a useful strategy is represented by the structural constriction of such elements in a blocked conformation, such as bicyclic structures. With respect to the Glennon pharmacophore model for σ 1 R ligands, the (piperazin-2-yl)alkanol moiety was incorporated in bicyclic frameworks, giving rise to different classes of compounds with a moderate-to-high affinity toward the σ 1 R (general structure in Figure 14 ). 124−129 SARs were described for these derivatives. In general, lipophilic substituents at both nitrogen atoms were required for a proper binding with the σ 1 R. The R 2 group could be an allyl substituent if the carbon atom linked to R 3 was unsubstituted; otherwise, this unsaturated moiety was not tolerated. In all other cases, R 2 could be a benzyl, propyl, or dimethylallyl moiety. The R 3 substituent could be a benzyloxy group if the bridge was made of four carbon atoms. By contrast, if the benzyloxy group was present, a smaller bridge led to a lower affinity. Thus, a benzylidene moiety was allowed. Besides, R 3 could be a hydroxy group or a carbonyl function only if R 2 corresponded to a benzyl moiety. Substituents that decreased the basicity of the nitrogen atom linked to R 2 , for example, phenyl or benzoyl, were not tolerated. Finally, bridge annulation with a quinoline or an indole ring or its participation in the formation of spirocycles caused a loss of affinity. In 2007, the synthesis of constrained derivatives of (piperazin-2-yl)propanols possessing a 6,8-diazabicyclo[3.2.2]nonane scaffold and a three-carbon bridge was reported ( Figure 14) . 130 Among these derivatives, enantiomeric alcohols 29 and 30 ( Figure 14) gave the best results in terms of activity and selectivity. Interestingly, compound 29 was about 30-fold more potent than its corresponding flexible piperazine 28. The diastereoisomeric alcohols of 29 and 30 (not shown) were about 20-fold less potent (6.5 nM vs 125 nM for compound 29 and its diastereoisomer, 7.5 nM vs 118 nM for compound 30 and its diastereoisomer), suggesting that the orientation of the alcoholic function at the 2-position was somehow crucial to establish a proper interaction with a HBA present in the binding site of the σ 1 R. Also, the authors observed that the alcoholic function of compounds 29 and 30 had a similar spatial orientation of the alcoholic group of compound 26.

In 2010, Sunnam and co-workers, as a continuation of the work previously described, expanded the carbon bridge of 6,8diazabicyclo[3.2.2]nonanes from three to four carbon atoms, affording 7,9-diazabicyclo[4.2.2]decane derivatives (compounds 31−37, Figure 14 ). The authors investigated if ring homologation and modification of the alcoholic function at the 2-position or its complete deletion could affect the activity of this novel class of compounds. Correctly, the homologous compound 29 (alcohol 31, Figure 14 ) had only a moderate affinity toward the σ 1 R, whereas the affinity for the σ 2 R fell in the micromolar range. Etherification of the alcoholic function of 31 led to alkyl ethers 32−34. Except for 34, which possessed a branched isopentyl moiety (σ 1 K i = 123 nM), ethers 32 and 33 displayed a worse affinity for the σ 1 R when compared with compound 31. Elongation of the alkyl chain or insertion of an aromatic ring led to ethers with very low affinity for the σ 1 R (not shown). Also, the authors performed similar structural modifications for the diastereoisomeric alcohols and ethers of 31−34. It was reported that the σ 1 R affinities of such diastereoisomers fell in the micromolar range, emphasizing that in the postulated bioactive conformation, the substituent in position 2 must possess the same spatial orientation observed for compounds 29 and 31. Removal of the oxygen atom led to alkane 35 with a σ 1 R affinity comparable to 31 (253 nM vs 298 nM, respectively). 131 Moreover, insertion of a double bond between carbons in positions 2 and 3 on the carbon bridge afforded compound 36, representing the best compound of this series in terms of σ 1 R affinity. Indeed, compound 36 was about 40-fold more potent than 31 (7.5 nM vs 298 nM, respectively). Unfortunately, compound 36 also displayed the best K i value for the σ 2 R for this class of compounds (184 nM). Insertion of a fluorine atom at the 2-position of the double bond led to compound 37 whose σ 1 R affinity was once again comparable with those of compound 31. Interestingly, the A427 cell line was susceptible to haloperidol, a well-known σ 1 R antagonist, so that the authors hypothesized that compound 36 could act as a σ 1 R antagonist, explaining its antiproliferative activity. However, the same assumption cannot be made for the 5637 cell line, which is insensitive to haloperidol. For these reasons, in our opinion, the assumption of functional activity based on the simple comparison of the biological effect with a reference compound, like haloperidol, is misleading. For this reason, the precise mechanism of cytotoxicity should be investigated more in detail to establish if the cytotoxic properties of compound 36 depend on the selective interaction and inhibition of the σ 1 R. 132 These compounds were designed for the same purposes previously discussed for the 7,9-diazabicyclo[4.2.2]decane series. The authors hypothesized that if rigidification of 28 into compound 29 afforded a 30-fold improvement of the σ 1 K i affinity value, then similar results should also be achieved by rigidification of the flexible (piperazin-2-yl)-ethanol structure (general structure in Figure  13 ) into the 2,5-diazabicyclo[2.2.2]octane scaffold (i.e., 38− 43, ent-38−43, Figure 15 ). The best results in terms of σ 1 R binding (calculated in animal and human myeloma cell lines) were obtained when a cyclohexylmethyl moiety was linked to one nitrogen atom of the bicyclic piperazine (Table 2) .

Almost all compounds displayed a σ 1 K i value <20 nM in guinea pig homogenate, except ent-38 and 43. In general, Nbenzyl derivatives 38, ent-38, 39, and ent-39 unveiled better σ 1 K i values for the 1-naphtylmethyl and biphenylmethyl derivatives 40−43 and ent-40−43 in both animal and human radioligand binding assays (σ 1 K i RPMI 8226 cell line <3.0 nM). Interestingly, the 1S,4R,7S configuration ensured the best σ 2 K i /σ 1 K i selectivity ratio (90-fold for ent-39, 230-fold for ent-41, and 55-fold for ent-43). Among all compounds, the naphtylmethyl derivative ent-41 showed the best affinity toward the σ 1 R (σ 1 K i guinea pig brain = 0.50 nM). Generally, stereochemistry seemed to not represent a relevant factor for proper binding to the σ 1 R. Surprisingly, structure rigidification did not significantly improve the σ 1 K i values for this class of compounds. Indeed, the authors compared the K i values of these novel bicyclic piperazines with those of their parent In addition, these studies also highlighted the binding determinants of bicyclic piperazine derivatives as follows: (i) the cyclohexyl methyl moiety is buried in a hydrophobic pocket of the receptor; (ii) the aromatic portion of the molecule is involved in the formation of π−π and π-cation interactions; (iii) the nitrogen atom linked to the aryl methyl moiety establishes a salt bridge bond with the carboxylic residue of Asp126; and (iv) the hydroxy group assumes the role of a HBA ( Figure 16 Considering that the induced growth inhibition effect mediated by these compounds on A427 cells was similar to that of haloperidol, the authors assumed that 2,5diazabicyclo[2.2.2]octanes acted as σ 1 R antagonists. However, we would like to stress that as a good practice in defining the putative functional role of new σR ligands, additional in vivo studies (e.g., formalin mice assay) are needed to validate such generalizations.

3.2. Selective σ 2 R Ligands. To date, the development of truly selective σ 2 R ligands has been challenging due to the vast and heterogeneous range of structures that can fit into the σ 2 R binding site. These chemical classes include conformationally restricted amines (e.g., benzomorphan-7-one, granatane, and methanobenzazocine derivatives), indole analogs compounds (e.g., siramesine-related derivatives), 133 and cycloalkyl amines with a flexible alkyl linker (e.g., N-cyclohexylpiperazine, N-(4fluorophenyl)piperazine, and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives). 134−136 A few examples of such representative structures are depicted in Figure 17 . Concerning their cytotoxicity properties, siramesine showed to induce cell death through a p53-and caspase-independent apoptotic pathway. 72 On the other hand, the dose-dependent effect exerted by the tropane derivative RHM-138 was mediated by caspase-dependent apoptosis. 137 The highly selective granatane derivative WC-26 and the cyclohexylpiperazine derivative PB28 enhanced the cytotoxicity of existing anticancer drugs, such as doxorubicin, by increasing the intracellular reactive oxygen species (ROS) or decreasing the expression of the Pglycoprotein (P-gp), respectively. 138, 139 Finally, benzamide derivative RHM-1 did not induce cytotoxicity and caspase-3 activation. However, due to the favorable binding profile, it was radiolabeled and further developed as a PET tracer for cancer diagnosis. 140 3.2.1. Conformationally Restricted Amines: Selective Granatane Derivatives. The σRs' ability to bind tropanebased molecules, including cocaine, 141 drove much of the early interest in the development of this class and structurally related compounds such as granatane derivatives. 138, 142, 143 In 2010, Hornick et al. evaluated the capability of a novel granatanebased σ 2 R ligand to induce apoptosis and augment standard chemotherapy in pancreas cancer. 144 SW-43, bearing a 9azabicyclo[3.3.1]nonan-3α-yl ring with an aminoalkyl extension, showed a higher effect on tumor cell viability when compared to the structural related analog SV-119 ( Figure 18 ), even though a loss of σ 2 R affinity and selectivity occurred. Indeed, shortening the length of the aminoalkyl chain from 10 (SW-43) to 6 (SV-119) carbons increased the σ 1 K i /σ 2 K i selectivity ratio significantly (19 vs 273). 143 However, the higher lipophilicity of SW-43 might have helped to enhance the membrane diffusion into the cell. 144 Moreover, the in vivo antitumor effects of the commercially available siramesine were also compared with that of the two granatane-based compounds. Thus, σ 2 R ligands treatment decreased tumor volume to the same extent as gemcitabine, while the combination of compound SW-43 with gemcitabine resulted in a superior effect in the stabilization of tumor volume than other tested compounds. 144 The primary amine function of compound SW-43 was successively condensed with 4-chloro-7-nitrobenzo-2-oxa-1,3diazole or 5-(dimethylamino)naphthalene-1-sulfonyl chloride ( Figure 18 ), which acted as fluorophores, to develop novel fluorescent σ 2 R selective ligands SW-120 and SW-116 for imaging of cell proliferation. 145 SAR analysis on granatane analogs suggested that a broad range of N-substitutions of the 9-azabicyclo[3.3.1]nonane was highly tolerated. Indeed, the introduction of extraordinarily long and large substituents (e.g., ω-amino groups and substituted benzo-fused heterocycles) did not affect σ 2 R affinity and selectivity significantly (WC-26 vs SV-119), while the N-substitution bearing an additional nitrogen atom located at least five carbon units apart led to increased affinity for the σ 2 R. Finally, the presence of aryl groups on the N-substituent was not essential for both affinity and selectivity for the σ 2 R (SW-43), although it was permitted.

In a follow-up study, the structure of SW-43 was conjugated with that of a second mitochondria-derived activator of caspase (SMAC) compound to develop an innovative class of tumortargeting drug delivery agents for treating ovarian cancer. 146 As a result, the new hybrid compound named SW III-123 ( Figure  18 ) retained a sufficient σ 2 R affinity to allow the successful delivery of the SMAC compound into ovarian cancer cells. The finding was supported by the potent cytotoxic effect of the new compound toward different human ovarian cancer cell lines (i.e., SKOV-3, CaOV-3, and BG-1) after 24 h treatment, which was not due to synergistic effects of the two molecules since their combination produced less cytotoxicity than the conjugated compound. 146 The strategy proposed by Zeng et al. was an interesting attempt; however, a significant limitation is the absence of either improved cytotoxic effect or synergism between the simultaneous modulation of the two targets. From our perspective, a different conjugation strategy (e.g., not cleavable vs cleavable linker) of the two active small molecules might be beneficial to overcome this issue. Therefore, as a future investigation, we suggest applying the mutual prodrugs approach to develop novel conjugates with bivalent function, that is, to obtain the synergistic effect and develop an effective drug delivery system. Consequently, by using selective σ 2 R ligands as a suitable promoiety, it might be possible to take advantage of both its antiproliferative effect (active promoiety) and tumor-targeting drug delivery properties (carrier promoiety).

3.2.2. Siramesine-Related Compounds: Selective Indole Derivatives. Siramesine ( Figure 17 ) has been reported, by Perregaard et al. in 1995, as a first selective σ 2 R ligand with relatively low affinity for additional off-targets, including 5-HT 1A R, 5-HT 2A R, D 2 R, and α 1 R. 133 Although siramesine was initially developed as a nontoxic CNS agent with potent anxiolytic activity, 147−150 later, it has been extensively evaluated both in vitro and in vivo for its antitumor properties and used as a reference σ 2 R agonist accordingly. 151−155 Nevertheless, it has been demonstrated that siramesinemediated cell death was likely due to the modulation of multiple molecular targets rather than through exclusively σ 2 Rs Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective activation. 156 Precisely, siramesine seemed to act as a lysosomotropic agent able to impact lysosomal membrane permeabilization and leakage, leading to increased ROS and triggering apoptosis signaling and cell death. 72,152 More Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective recently, the combination of siramesine and lapatinib (a dual tyrosine kinase inhibitor) was reported to induce cell death in MDA MB-231 and SKBR3 breast cancer cell lines mediating ferroptosis and autophagy through an unclear synergistic effect. 157 Since its discovery, the chemical structure of siramesine has been manipulated to obtain improved highly selective indole analogs ( Figure 19 ). Mainly, modification of both the indole scaffold and the spiropiperidine moiety was carried out; thus, structural determinants for this class of σRs ligands were extensively explored. 109, 110, 158, 159 Earlier SAR studies on indole analogs revealed that a concurrent presence of a butyl chain as a spacer and a 4fluorophenyl substituent at the indole ring increased the σ 2 R selectivity considerably. 133 On the other hand, the arylpiperidine moiety induced higher σRs affinity than arylpiperazine (45 vs 44) , while their replacement with a spiro-[isobenzofuran-l(3H),4′-piperidine] resulted in a more selective compound (siramesine vs 44 and 45). Concerning the σ 1 K i /σ 2 K i selectivity ratio, the best result was obtained by the tropane derivative 46.

A subsequent study aimed to determine the structural elements leading the σRs affinity and selectivity within the indole analogs class was performed by synthesizing spirojoined benzofuran, isobenzofuran, and benzopyran piperidine derivatives. 109 Accordingly, two major critical features were found: (i) larger lipophilic N-substituents at the spiro-joined isobenzofuran ring promoted the σ 2 R affinity (H < Me < Et < i-Pr < n-Pr < n-Bu < (CH 2 ) 4 Ph); and (ii) a substituent at the benzene ring of the spiropiperidine system greatly affected the σ 1 R/σ 2 R ratio (i-Pr < Me < 4-CF 3 < 4-F < 7-F), as exemplified by 47, while changing in the geometry of the spiro-system (e.g., benzofuran and benzopyran) decreased the σ 2 R affinity. Finally, exchanging the isobenzofuran portion of siramesine with the thioisobenzofuran moiety further increased the σ 2 R selectivity (siramesine vs 48).

Niso et al. described the development of novel σ 2 R agonists as possible antitumor agents in multidrug-resistant cancers. 158 The newly synthesized compounds possessed different and heterogeneous scaffolds, such as 1-(4-fluorophenyl)-1H-indole, 1H-indole, 5-methoxy-1,2,3,4-tetrahydronaphthalene, and 9Hcarbazole, which were selected based on the structure of different reference compounds, for instance, siramesine, PB28, and F281 ( Figure 20) . Also, to combine the structural features probably responsible for high σ 2 R affinity, specific cyclic amine moieties ( Figure 20) were alternatively connected to the scaffolds forming four different series. Among the indole series, the N-substituted analogs were more selective for the σ 2 R than N-unsubstituted ones (49 vs 50). Thus, the authors suggested that the preferred σ 1 R affinity observed for indole analogs might be due to an additional hydrogen bond formed between the NH group belonging to the indole and the σ 1 R. These data were consistent with that previously reported by Perregaard et al. On the other hand, the σ 1 R affinity value of siramesine (K i = 10.5 nM, Figure 20 ) was found to be much higher than discovered initially, causing a tremendous reduction of the σ 1 K i /σ 2 K i selectivity ratio. 158 For the sake of clarity, these inconsistent data are indeed most likely due to the slightly different binding protocols adopted. Similarly, PB28, originally described as a high-preferred σ 2 R agonist (σ 1 K i /σ 2 K i = 40), was found to possess a more significant affinity for the σ 1 R (σ 1 K i = 0.38 nM and σ 2 K i = 0.68 nM). Despite the σ 1 R/σ 2 R mixed profile of PB28, this cyclohexylpiperazine derivative emerged as one of the most potent putative σ 1 R antagonist/ σ 2 R agonist known until today, and as we will discuss in the next section, it has been extensively studied both for its biological activity and the SAfiRs as a lead compound. 160 Interestingly, PB28 has been recently tested for its in vitro anti- Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective SARS-CoV-2 activity, and it was found to be more potent and less cardiotoxic than hydroxychloroquine, supporting further studies as a promising pan-viral candidate. 161 Compound 49 (Figure 20) , a siramesine analog, displayed notable σ 2 R selectivity over the σ 1 R subtype as well as significant antiproliferative activity in human breast cancer cells, either sensitive or resistant to doxorubicin (EC 50 = 17.8 and 21.8 μM, in MCF-7 and MCF-7/dox, respectively). Furthermore, 49 interacted with P-gp stronger than siramesine (EC 50 = 0.21 and 1.41 μM, respectively) and restored the antitumor activity of doxorubicin after co-administration with it, suggesting efficacy in cells with P-gp-induced resistance. 158 In 2015, Xie et al. reported the synthesis, SAfiRs, and antiproliferative activity of a series of indole-based σ 2 R ligands derived from siramesine. 159 To develop new σ 2 R ligands and find valuable radiotracers for tumor imaging, the authors applied three different modifications to the siramesine's structure (51−53, Figure 21) . Notably, both the spiro-joined isobenzofuran and the indole N-substitution regions of siramesine were explored by replacing them with different preferred σRs cyclic amines, including 5,6-dimethoxyisoindoline (51), 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (52), 4-phenylpiperidine-4-carbonitrile (53) , and different fluoroalkoxy-phenyl-piperazines (not shown), or with a 2-fluoroalkyl group (52) and a N-(4-iodophenyl) group (53), respectively. Subsequently, both portions were concurrently modified, like in 53. SARs performed on this series were consistent with previously reported studies, confirming the critical role of both the σ 2 R-preferred cyclic amine motif and the N-(4fluorophenyl)indole scaffold to increase the σ 2 R affinity and selectivity. On the other hand, a consistent discrepancy in the σ 2 Ki values with those reported by Niso et al. was observed for compound 49 (σ 1 K i = 530.8 nM and σ 2 K i = 49.2 nM vs σ 1 K i = 1,390 nM and σ 2 K i = 5.34 nM) which resulted in a substantial loss of subtype selectivity (σ 1 K i /σ 2 K i = 260 vs 11). Nevertheless, compounds 49 and its 5,6-dimethoxyisoindolineanalog (51) (σ 1 K i = 255.6 nM and σ 2 K i = 53.8 nM) were tested in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate their antiproliferative activity in DU145, MCF-7, and C6 cancer cells along with siramesine used as a reference compound. Both compounds showed EC 50 values comparable to that of siramesine in all the tested cell lines, with the highest antiproliferative activity exerted by 51 in MCF-7 cells (EC 50 = 17.0 μM). Moreover, cell cycle analysis using flow cytometry revealed that 49, 51, and siramesine induced G 1 phase cell cycle arrest in DU145 cells.

Very recently, compound 49, with other two low-affinity σ 2 R ligands (not shown), was reported as the first-in-class multidrug resistance-associated protein 1 (MRP1) modulator acting as a collateral sensitizer. 162 Higher cytotoxicity effects were observed in the MRP1 overexpressing cells (i.e., MDCK/ MRP1 and A549/DX) than in the wild-type counterparts, supporting the involvement of the collateral sensitivitymediated activity. Furthermore, co-administration of 49 with cisplatin in a A549/DX xenografts model showed a significant reduction in tumor growth, while the single-agent administration did not. 162 3.2.3. Cycloalkyl Amines with Flexible Alkyl Linker: Substituted Piperazine/Piperidine and Tetrahydroisoquinoline Derivatives. 3.2.3.1. Cyclohexylpiperazine and Cyclohexylpiperidine Analogs. Cyclohexylpiperazine derivatives represent a broad set of well-studied σRs ligands, with PB28 ( Figure 17 ) being the prototype compound for this class. This tetralin-based σR-preferred ligand has been extensively investigated for its anticancer properties, 36, 41, 163 and many PB28 related analogs were prepared over the past years. 164 Particularly, specific modifications of the PB28 structure, aiming to obtain optimal log P and log D values to reduce nonspecific binding and improve cancer cells intake of new analogs, were performed. 103 With this in mind, in 2011, Abate et al. synthesized new PB28 analogs with reduced lipophilicity by introducing a polar functional group (i.e., amine, amide, or ether group) in the propylene linker or by replacing the tetralin with a chromane nucleus ( Figure 22 ). In addition, pure enantiomers were obtained whenever possible, and a naphthalene ring instead of the tetralin one was used to evaluate the effect of the chirality on the σ 2 R affinity. Unfortunately, none of the newly less lipophilic analogs showed better affinity or selectivity than PB28. Compound 54 ( Figure 22 ) displayed the best binding profile through the series and suitable lipophilicity to enter tumor cells. However, 54 did not exert antiproliferative activity in SK-N-SH cells, while it showed specific activity toward the P-gp efflux pump (EC 50 = 8.1 μM), suggesting a few limitations in its further development as a diagnostic or therapeutic agent. Interestingly, these results, along with previously reported ones from the same authors, 165 supported the fact that lipophilicity played a pivotal role in the σ 2 R activity. In contrast, the enantioselectivity had only a marginal effect on receptor subtypes interactions. Based on σRs binding data and the extensive modifications performed on PB28 structure (55− 58 and PB221, Figure 23 ), the following SAfiRs can be summarized: (i) introduction of a polar functional group either in the propylene linker or in the tetralin scaffold of PB28 reduced the σ 2 R affinity (PB28 vs 55 and 56); (ii) piperazine ring replacement or opening led to decrease of the σRs affinity (PB28 vs PB221); (iii) modification of the N-atom connected to the cyclohexyl group (e.g., substitution, quaternization or incorporation into an amide function) mainly affected the affinity at the σ 1 R subtype (PB28 vs 57); however, the presence of both basic N-atoms is needed for higher σ 2 R affinity; and (iv) a cyclohexyl group as a substituent at the piperazine ring is optimal for the σRs affinity (PB28 vs 58).

The preclinical efficacy toward pancreatic tumor models of PB28-related compounds, including F281 and PB221, was investigated by Pati et al. 36 The cytotoxic effect after 24 h exposure to the tested compounds was assessed on different human and mouse pancreatic cancer cell lines (i.e., MIAPaCa-2, BxPC3, AsPC-1, Panc-1 and Panc02, KP-2, and KCKO, respectively). Heterogeneous outcomes on cell viability were observed in a cancer cell lines manner. For example, the cytotoxic effect was more significant for specific cell lines such as Panc02, while AsPC1 and Panc-1 resulted in the most resistance among the selected cell lines. Among the tested ligands, both F281 and PB221 displayed the best in vitro antiproliferative profile toward the cells panel. A significant increase in caspase-3 in vitro activity was detected for PB221, supporting the caspase-dependent apoptotic pathway mediated by its σ 2 R activity. Also, a substantial increase in mitochondrial superoxide radical production was observed. On the other hand, generally, a poor match between in vitro and in vivo efficacy occurred, except for daily treatment with PB28, which produced a similar in vivo effect to that of gemcitabine alone. To justify these results, the authors suggested the formation of active metabolites for the most potent compounds. However, no metabolic stability studies were performed to support this speculation.

Very recently, the antitumor effect of the 4-cyclohexylpiperidine derivative PB221 on an anaplastic astrocytoma tumor model has been explored. 79 To pursue this goal, both the murine brain tumor cell line ALTS1C1 and the murine pancreatic cell line UN-KC6141 were initially used to examine the compound's cytotoxic properties. The IC 50 values of PB221 were found to be 10.61 μM and 13.13 μM for ALTS1C1 and UN-KC6141 cell lines, respectively. However, α-tocopherol (but not N-acetylcysteine) counteracted these effects, suggesting the involvement of mitochondrial superoxide production. 79 Besides, in vivo studies performed on C57BL/6 J mice showed that PB221 delayed tumor growth up to 36% compared to the control and increased the survival time from 26 to 31 days in the orthotopic tumor model. Interestingly, PB221 was well tolerated at the tested dose (1 mg/mouse/injection), showing similar side effects to the approved drug Temozolomide.

3.2.3.2. N-(4-Fluorophenyl)piperazine Analogs. McCurdy and co-workers carried out extensive research on developing selective σ 2 R probes to elucidate the receptor's functional roles i n s e v e r a l m e d i c a l c o n d i t i o n s , i n c l u d i n g c a ncer. 51, 55, 138112, 166, 167 Notably, in 2015, Nicholson et al. reported the pharmacological characterization of a σ 2 Rpreferred ligand bearing the N-(4-fluorophenyl)piperazine as a cyclic amine moiety (CM572, Figure 24 ). 166 This new compound was initially developed within a set of isothiocyanate analogs of SN79 (Figure 24) , a well-characterized mixed σ 1 R/σ 2 R antagonist (σ 1 K i = 27 nM, and σ 2 K i = 7 nM). To obtain irreversible σ 2 R binding, the authors incorporated the isothiocyanate group at the 6-position of the 1,3-benzoxazol-2(3H)-one scaffold. Furthermore, the introduction of the 6isothiocyanate moiety (CM572) instead of the 6-acetyl group (SN79) was detrimental for the σ 1 R binding, with a consequent increase of the σ 2 R selectivity (σ 1 K i /σ 2 K i = 685, Figure 24 ). Interestingly, CM572 showed a dose-dependent calcium response in a neuroblastoma cancer cell line (SK-N-SH) at higher doses, supporting its partial agonist properties at the σ 2 R. Subsequently, the cytotoxicity of CM572 was evaluated against three different cancer cell lines (i.e., SK-N-SH, PANC-1, and MCF-7) as well as toward normal cells such as primary epidermal melanocytes and human mammary epithelial cells. As a result, the cytotoxic effect for CM572 was higher in cancer cells than normal cells, significantly CM572 showed to induce dose-dependent cell death (EC 50 = 7.6 μM) after 24 h treatment of SK-N-SH cells. 166 The same research team investigated the non-apoptotic and stimulatory effects on glycolytic cellular metabolism exerted by some of their σ 2 R selective ligands. In particular, based on the pharmacological characterization of compound CM764, a new metabolic regulatory function for σ 2 R was proposed. The novel benzoxazolone analog of SN79, which differed from the parent compound only in the amino group at 2-position of the 4fluorophenylpiperazine moiety (Figure 24 ), was initially assessed in a radioligand binding competition assay, revealing 25-fold selectivity over the σ 1 R with an improvement in the σ 2 R affinity (CM764 vs SN79). Interestingly, CM764 increased the MTT reduction in SK-N-SH neuroblastoma cells without inducing changes in cell viability or cell proliferation. In addition, the increase in MTT reduction was partially or entirely blocked by different σ 2 R antagonists, suggesting a σ 2 R-mediated mechanism. Moreover, the overall stimulatory effect included an increased level of NAD + /NADH and ATP, a reduction in ROS, and an increment of both the hypoxia-inducible factor 1α and the vascular endothelial growth factor levels. Altogether, the data suggested that σ 2 R ligands with different functional profiles could modulate dual cellular pathways (death vs survival). 112 In a more recent study, the divergent cytotoxic and metabolically stimulative effects of N-(4-fluorophenyl)piperazines were further examined. 167 Also, the structural determinants required to design selective σ 2 R with predicted dual functions were analyzed. The tested series encompassed σR ligands structurally related to compounds CM572 and SN79 (included), where single-element variations at the 6position of the 1,3-benzoxazol-2(3H)-one, 3-methyl-1Hbenzimidazol-2-one, and 1,3-benzothiazol-2(3H)-one heterocyclic systems were applied (CM458, WA403, and WA435, Figure 24 ). Compound CM458 bearing a nitro functional group at the 6-position of the benzoxazolone ring stood out for its subnanomolar affinity at the σ 2 R (K i = 0.56 nM), while the Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective 5-amino-3-methyl-benzimidazolone analog WA403 showed the best selectivity ratio (σ 1 K i /σ 2 K i = 167) among the series.

Generally, an isothiocyanate group as a substituent reduced the σ 1 R affinity, thus increasing the σ 2 R selectivity (CM572 and WA435 vs SN79, Figure 24 ). However, for the benzothiazolone analog WA435, the loss of σ 1 R affinity was less remarkable. Notably, the new SN79 analogs were at least 25fold more selective for the σ 2 R than the parent compound.

Concerning the divergent effects elicited by N-(4fluorophenyl)piperazine analogs, the following SARs were found: (i) introduction of the 6-isothiocyanate group, regardless of heterocycle, potently induced programmed cell death most likely due to the irreversible receptor binding; (ii) substitution at the 6-position with acetyl, nitro, amino, or fluorine did not produce a significant cytotoxic effect; therefore, the presence of a highly electron-withdrawing group is not sufficient to obtain cytotoxicity; and (iii) changing in the heterocycle system was not decisive for the divergent effect. Finally, other non-isothiocyanate derivatives, including SN79, possibly acting as putative σ 2 R antagonists, were tagged as "neutral" since they produced neither programmed cell death nor metabolic stimulation. 167 An interesting aspect of the SARs studies by Nicholson et al. is the proposed irreversible binding to the σ 2 R for the 6isothiocyanate derivatives which is possibly responsible for their cytotoxic properties. This effect on cell viability has been examined by extensive washing of SK-N-SH neuroblastoma cells after an acute exposure with the tested compounds followed by an incubation period with fresh media. Particularly, the 6-isothiocyanate derivatives might mediate the irreversible binding via covalent bond formation with specific amino acid residues bearing a nucleophilic group (i.e., serine and cysteine) within the σ 2 R binding pocket. From our standpoint, an integrated approach involving the synthesis of a Journal of Medicinal Chemistry pubs.acs.org/jmc Perspective larger set of various properly substituted derivatives (e.g., Michael acceptors) and in silico molecular modeling studies might help to define the exact mechanism of the irreversible binding mode. 3.2.3.3. 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline Analogs. Similar to the N-cyclohexylpiperazine and the N-(4-fluorophenyl)piperazine, the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety has been extensively used as a suitable σ 2 R-preferred cyclic amine fragment to develop selective σ 2 R ligands. To this extent, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinoalkyl benzamide derivatives (general structure, Figure  25 ) can be considered the most representative σ 2 R ligands prototype, even though Mach et al. initially developed them as a set of mixed dopamine receptor D 3 and σ 2 R ligands. 168 Indeed, since their discovery, this specific class of conformationally flexible amines showed high affinities and attractive selectivity for σ 2 R, making them useful chemical probes for imaging the σ 2 R in tumors with PET. 76, 169 A few examples of early developed 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs possessing a flexible benzamide scaffold (59−64) are depicted in Figure 25 . 136, 168 SARs studies on this first set of ligands elucidated the structural features required for high σ 2 R affinity and selectivity. The introduction of the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline gave superb selectivity (σ 1 K i / σ 2 K i = 1573) with a considerable reduction of binding with the dopamine receptors (59, Figure 25 ). Alkyl chain shortening, from four to two methylene units, did not affect the σ 2 R affinity (59 vs 60) . Similarly, removing the methoxy group at the 3-position of the benzamide ring did not significantly reduce the σ 2 R affinity nor the selectivity (61 vs 59 and 60). The introduction of methyl instead of bromo group was highly tolerated (62 vs 61). Regarding the 1,2,3,4-tetrahydroisoquinoline moiety, fusing methylene-, ethylene-, and propylenedioxy rings onto the tetrahydroisoquinoline ring was detrimental for both the affinity and selectivity at the σ 2 R (63 vs 59). Furthermore, the tetrahydroisoquinoline ring-opening led to an ultimate loss of affinity for the σ 2 R (64 vs 59). 136, 168 As an extension of their previous works on selective σ 2 R ligands, Sun et al. synthesized a new series of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs without the benzamide moiety. 170 In this new series, substituted benzene and quinazolin-4(3H)-one fragments acting as electron-deficient or electron-rich aromatic portions were linked through different alkyl length chains to the 6,7-dimethoxy-1,2,3,4tetrahydroisoquinoline moiety (general structures A and B, Figure 26 ). Unlike the quinazolin-4(3H)-one analogs, the new 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives showed high σ 2 R affinities with a good selectivity ratio (65 and 66, Figure 26 ). Specifically, the ketone reduction to the corresponding hydroxyl group was broadly tolerated without affecting the affinity and selectivity at the σ 2 R (65 vs 66). On the other hand, the introduction of an electron-deficient aromatic moiety such as the quinazoline scaffold as a hydrophobic domain led to a decrease of affinity and selectivity (e.g., 67 vs 65). Compound 66, possessing an excellent selectivity ratio, produced a cytotoxicity effect toward two different cancer cell lines (EC 50 = 12.50 μM for liver Huh-7, and EC 50 = 14.86 μM for esophagus KYSE-140) similar to that Surprisingly, compound 65 which shows a close σRs binding profile to analog 66 did not show any effect, suggesting that the biological activity might not be σ 2 R mediated. Very recently, Xie et al. further developed the series mentioned above by analyzing the impact of introducing additional methoxy groups to the tetrahydroisoquinoline moiety on the σRs binding profile. In particular, to increase the affinity and selectivity toward the σ 2 R subtypes, the electron-rich 2,3,4,5-tetramethoxytoluene scaffold was used as a hydrophobic portion (general structure, Figure 27 ). The new di-and trimethoxy-substituted tetrahydroisoquinolin-2-alkylphenones showed moderate to high affinity and selectivity for the σ 2 R. Analog 68 (Figure 27 ), bearing a five methylene linker between the phenone carbonyl portion and the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety, displayed the highest affinity and selectivity for the σ 2 R among all the benzamide derivatives reported so far (68 vs 59 and 65). Replacement of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety with 5,6,7-trimethoxy-or 6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline moieties led to a decrease in affinity for σ 2 R (68 vs 69 and 70). Despite the favorable σRs binding profile, no significant inhibitory effects on MCF-7 cancer cell lines were observed. Indeed, functional studies performed by measuring intracellular calcium concentration allowed their classification as putative σ 2 R antagonists. 171 In 2011, Abate et al. combined the structural determinants (i.e., benzamide scaffold and cyclic amine moieties) of their lead compound PB28 with the highly potent and selective σ 2 R ligands RHM-1 to develop new potential PET radiotracers. 172 Good results in terms of σ 1 K i /σ 2 K i selectivity ratio were obtained by 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives 71 and 72 ( Figure 28 ). However, the newly synthesized ligands also interacted with P-gp (e.g., EC 50 = 2.5 μM for 72), hence, limiting their further development as PET agents. A similar interaction with P-gp was observed for cyclohexylpiperazine analogs 73 and 74 ( Figure 28 ), which also showed higher binding at the σ 1 R with a parallel loss of σ 2 R selectivity. These results are consistent with recent σ 1 R molecular models developed by Niso et al. 173 which showed that the two methoxy substituents belonging to the tetrahydroisoquinoline ring might be placed in a sterically hindered region within the secondary hydrophobic domain of the σ 1 R binding pocket.

Interestingly, an intramolecular hydrogen bond between the 2-methoxy substituent and the N-atom of the benzamide group was proposed (general structure, Figure 28 ), suggesting a bicyclic-like active conformation for this set of derivatives. 172 Indeed, this hypothesis was corroborated by the σRs binding profile of the 3,4-dihydroisoquinolin-1(2H)-one derivative 75 ( Figure 28 ), in which the above-mentioned intramolecular bond has been mimicked by a rigid ring. 172 Therefore, in a subsequent study, Niso et al. further investigated the role of bicyclic-preferred conformation proposed for flexible benzamides as a suitable hydrophobic portion to target the σ 2 R. 174 The authors synthesized 3,4dihydroquinolin-(1H)2-one and 1,2,3,4-tetrahydroquinoline derivatives along with flexible anilide and aniline analogs linked to the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinoalkyl portion. Also, considering the good σRs binding profile and the appropriate lipophilicity showed by previously developed substituted 3,4-dihydroisoquinolin(2H)1-one derivatives (76 Figure 29) . Notably, anilide derivatives showed a lower binding for the σ 2 R than the corresponding anilines, probably due to the lack of partial rigidification that might occur in anilines because of the lone pair conjugation of the N-atom with the benzene ring with a resulting resembling bicyclic framework. 174 These data confirmed that a rigid bicyclic structure as a hydrophobic moiety was optimal for both affinity and selectivity for the σ 2 R. Surprisingly, none of the compounds exerted antiproliferative activity in human breast adenocarcinoma MCF-7 cells. However, since the modest interaction with the P-gp (EC 50 = 2.13 μM), appropriate lipophilicity (clogP = 3.94), and the presence of easily radiolabeling functions (i.e., 3-methoxy groups) of 79, the authors suggested its further development as a possible PET radiotracer.

Very recently, small molecules characterized by the presence of the 3-alkoxyisoxazole moiety have been designed and evaluated for their potential binding properties toward the σRs. 176 This chemical scaffold was identified from the superimposition of the pharmacophoric elements required for a righteous binding to both σ 1 and α4β2 nicotinic receptors. 177 Compound 82 ( Figure 30 ) was detected as a σ 1 R ligand with high affinity and selectivity over the σ 2 R subtype. Structural modifications of compound 82 were conducted to switch selectivity toward the σ 2 R and find potential anticancer compounds. The general structure of the developed 3-alkoxyisoxazole derivatives of 82 is depicted in Figure 30 . Insertion of electron-withdrawing substituents (fluorine, chlorine, trifluoromethyl) on the aryloxymethyl group linked to the 5-position of the isoxazole ring led to increased affinity values for the σ 2 R subtype. Particularly, meta-fluorine and meta-trifluoromethyl substitutions were preferred concerning substitutions in ortho and para positions. The trifluoromethyl substitution was more effective with a 15-fold increased σ 2 K i (data not shown) with respect to 82. On the contrary, electron-donating substituents such as a 

σRs represent a unique class of proteins involved in many physiopathological and pathological roles. Several immunohistochemical and radioligand binding assay studies revealed that both receptor subtypes are overexpressed in several cancer cell lines, suggesting a potential role of these proteins in cancer progression and tumor invasiveness. Moreover, the pharmacological modulation of σRs through small molecules has been proved to be a promising approach for developing novel therapeutics. However, although several studies supported the search for novel compounds targeting σRs to treat cancer, no compounds have reached the clinical phase yet. One of the reasons for this might be related to the heterogeneous and promiscuous biological effects exerted by certain σR ligands in preclinical studies, which are also related to the inconclusive evidence about the molecular role of the σRs in the etiopathogenesis and pathogenesis of cancer. Thus, there is still a need to answer crucial questions concerning the role and the involvement of σRs in tumor biology to reveal the real potential and benefit of the clinical use of σRs ligands in cancer chemotherapy. Indeed, an unambiguous characterization of the biological target is essential to link its perturbation to functional pharmacology. Moreover, several potent ligands, of both σRs subtypes, showed poor pharmacokinetic profiles. This fact hinders their clinical utilization as drugs and allows their use merely as diagnostic or pharmacological tools such as radioligand probes for PET scanning. We believe that this problem could be dealt with using the following strategies: (i) optimizing the ADME properties and the off-target effects, such as hERG binding, during the early stages of drug design;

(ii) using computational techniques when available, such as QSAR and toxicity prediction machine learning methods, to estimate the potential adverse effects of the drug candidates; and (iii) repurposing of certain Food and Drug Administration approved CNS drugs which, by definition, have wellestablished pharmacokinetic and safety profiles. The drug repurposing approach is especially useful in the case of σRs ligands because they already share some pharmacophoric features with other ligands of certain CNS targets such as the opioid and dopamine receptors, which is exemplified by the affinity of pentazocine and haloperidol, respectively, to the σRs.

As extensively described in this perspective, tremendous efforts to discover selective σR ligands with antiproliferative properties have been made by medicinal chemists in the last 10 years. These efforts led to the identification of various chemical prototypes; therefore, for a comprehensive overview, a summary of this information has been collected in Table 3 .

It is worth noting that the σ 2 R identity has been established only recently, and no crystal structure has been reported yet. Nevertheless, a variety of new selective σ 2 R ligands have been recently discovered, and the specific overexpression of σ 2 Rs in a broad panel of cancer cell lines has been elucidated. As a result, the potential ability to pinpoint the tumor cells in an early stage of the pathology makes σ 2 R ligands powerful molecular tools exploitable in diagnostics and theranostics. Conversely, the study reported by Zeng et al. 37 proved that the cytotoxicity exerted by some well-known σ 2 R ligands, including siramesine and PB28, was independent of the modulation of the σ 2 R. This finding corroborates the hypothesis that multiple unknown targets are likely involved in the observed cytotoxic effect mediated by σ 2 R ligands, making the overall scenario very intriguing. Besides, the recent identification by Abate and co-workers of σ 2 R ligands that promote collateral sensitivity in multidrug resistance cells further supports the hypothesis that a direct correlation between σ 2 Rs modulation and the observed cytotoxicity does not exist. Interestingly, collateral sensitivity is a well-studied phenomenon in cancer research. 179 Thus, the development of new σR ligands which exploit the mechanism of the synthetic lethality to induce selective cytotoxicity is emerging as a new successful strategy in the field. 162 Despite the lack of homogeneous evidence of one-to-one correspondence between σRs modulation and cytotoxicity, the involvement of these chaperons as key players in the tumorsupportive cellular machinery has been proved. Recently, Maher et al. 180 described the ability of σRs ligands in regulating the programmed death-ligand 1 (PD-L1) expression and activity in cancer cells, suggesting a novel therapeutic strategy acting on tumor immune microenvironments. Specifically, σ 1 Rs inhibition either by σ 1 R negative modulators or using shRNA-induced PD-L1 autophagic degradation in breast and prostate cancer cells, suggesting the possibility of combining σRs modulators with specific drugs that can induce PD-L1 degradation (e.g., gefitinib), therefore enhancing the antitumor activity. 181 However, the effectiveness of possible drug combinations might be mitigated by undesirable drug interactions and interferences. Alternatively, polypharmacology represents a current paradigm to enhance the efficacy of new anticancer agents. 182, 183 More specifically, in this case, selected molecular entities having the ability to intercept other validated molecular targets involved in the tumor progression and aggression can be effectively combined with structural determinants belonging to σR ligands to obtain novel multitarget ligands. As an example, Mangiatordi et al. 184 have recently described their perspective on an innovative polypharmacology approach involving the concurrent targeting of cannabinoid receptor subtype 2 (CB 2 R) and σRs for cancer. Particularly, taking advantage of both the common pharmacophoric elements and the anticancer activities of CB 2 R agonists and σRs modulators, the authors proposed the development of molecular hybrids, that is, dual CB 2 R/σR ligands, potentially able to modulate different cancer pathways synergistically.

We expect the interest in the development of σRs ligands to continue for the next few years as tumor diagnostic tools as well as chemotherapeutic agents, perhaps as adjuvant therapies. Moreover, the availability of the σ 1 R crystal structure and the potential crystallization of the σ 2 R in the near future would give momentum to this research field. Finally, we believe that the recent discovery of repurposing some σRs ligands for fighting the early stages of COVID-19 could draw more attention to these biological targets. Altogether, this article represents a comprehensive literature review that might help to provide a reader with a perspective on the development of potent σRs ligands as additional weapons exploitable in anticancer therapy. , multidrug resistanceassociated protein 1; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; n-Bu, normal butyl; NMDA, N-methyl-D-aspartate; n-Pr, normal propyl; Nsp6, nonstructural protein 6; OXAIPN, oxaliplatin-induced peripheral neuropathy; PD-L1, programmed death-ligand 1; PET, positron emission tomography; PET−MRI, positron emission tomography−magnetic resonance imaging; P-gp, P-glycoprotein; PGRMC1, progesterone receptor membrane component 1; Ph, phenyl; PI, positive ionizable; p-Me, para-methyl; QSAR, quantitative structure− activity relationship; RNAi, RNA interference; ROS, reactive oxygen species; SAfiR, structure−affinity relationships; SAR, structure−activity relationships; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SERT, serotonin transporter; shRNA, short hairpin RNA; SIGMAR1, sigma nonopioid intracellular receptor 1 gene; SMAC, second mitochondria-derived activator of caspase; TMEM97, transmembrane protein 97; σR, σ receptor

Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality

Nanotherapeutics to overcome conventional cancer chemotherapy limitations

Combining immunotherapy and targeted therapies in cancer treatment

Novel molecular targets in cancer chemotherapy waiting for discovery

Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes

Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease

The Molecular Function of σ Receptors: Past, Present, and Future

Psychotomimetic opioid binding: specific binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain

The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog

Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export

Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes

Pharmacologic effects of N-allylnormetazocine (SKF-10047)

Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes

Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety, tested in two laboratory models in mice

Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction

The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson's Disease (PD) and Major Depressive Disorder (MDD)

Purification, molecular cloning, and expression of the mammalian sigma1-binding site

A proposal for the classification of sigma binding sites

Crystal structure of the human σ1 receptor

Structural basis for σ(1) receptor ligand recognition

Bezprozvanny, I. Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases

Blockade of Cocaine or σ Receptor Agonist Self Administration by Subtype-Selective σ Receptor Antagonists

Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?

Identification of the gene that codes for the σ

Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site

Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex

The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception

Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines

Are sigma modulators an effective opportunity for cancer treatment? A patent overview

Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity

Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity

Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer

TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death

Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia

Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells

Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels

Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines

Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture

Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability

Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands

Screening of antiglioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines

Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines

Sigma ligands inhibit the growth of small cell lung cancer cells

Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ 1 receptor affinity

The pharmacology of the novel and selective sigma ligand, PD 144418

Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells

CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity

Ibogaine possesses a selective affinity for σ2 receptors

Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity

]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents

Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice

(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans

Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study

Identifier: NCT02753101, [18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica

Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain

Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2−73, a novel aminotetrahydrofuran derivative

A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-betainduced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons

Binding properties of SA4503, a novel and selective sigma 1 receptor agonist

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke

Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

Sigma1 Pharmacology in the Context of Cancer

Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo

Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines

Functional assays to define agonists and antagonists of the sigma-2 receptor

Assessment of cellular proliferation in tumors by PET using 18F-ISO-1

Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status

The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer

In vitro and in vivo sigma 1 receptor imaging studies in different disease states

Approaches to PET Imaging of Glioblastoma

Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor

A structure-affinity and comparative molecular field analysis of sigma-2 (sigma2) receptor ligands

Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives

Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor

A 3D-pharmacophore model for sigma2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives

A New Pharmacophore Model for the Design of Sigma-1 Ligands Validated on a Large Experimental Dataset

Development of Tetrahydroindazole-Based Potent and Selective Sigma-2 Receptor Ligands

Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the "deconstructionreconstruction-elaboration

A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines

Virtual Screening for Ligand Discovery at the σ(1) Receptor

On the Integration of In Silico Drug Design Methods for Drug Repurposing

Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation

HIF-1alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole

Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress

SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo

SR31747A: a peripheral sigma ligand with potent antitumor activities. Anti-Cancer Drugs

Characterization of the cocaine binding site on the sigma-1 receptor

Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe

Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli

Synthesis and characterization of N,N-dialkyl and Nalkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors

Is a nitrogen atom an important pharmacophoric element in sigma ligand binding?

Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane

Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer

Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system

+)-Morphine attenuates the (−)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord

Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain

Spiropiperidines as high-affinity, selective sigma ligands

Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines

Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1

Exploitation of an additional hydrophobic pocket of σ1 receptors: late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization

Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma

Pharmacological characterization of high-affinity σ(1) receptor ligands with spirocyclic thienopyran and thienofuran scaffold

Thiazole-Based σ(1) Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles

Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands

Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes

Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor

Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes

Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds

Characterization of novel N,N'-disubstituted piperazines as sigma receptor ligands

Coop, A. 1,4-dibenzylpiperazines possess anticocaine activity

Chiral, nonracemic (piperazin-2-yl)methanol derivatives with sigma-receptor affinity

Homologous piperazinealcanols: chiral pool synthesis and pharmacological evaluation

Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes

Synthesis of bridged piperazines with sigma receptor affinity

Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity

Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity

Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity

Bicyclic sigma receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate

Synthesis of bicyclic sigma receptor ligands with cytotoxic activity

Synthesis and biological evaluation of conformationally restricted σ(1) receptor ligands with 7,9-diazabicyclo

Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?

Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles

4-(tetralin-1-yl)-and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity

Benzimidazolone-based selective σ(2) receptor ligands: Synthesis and pharmacological evaluation

Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for sigma receptors

Sigma-2 ligands induce tumour cell death by multiple signalling pathways

]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents

Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer

Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer

Sigma receptors: potential medications development target for anti-cocaine agents

The analgesic tropane analogue (±)-SM 21 has a high affinity for sigma2 receptors

Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes

Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer

N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands

Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine

Synthesis of (+)-and (−)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for sigma1 and sigma2 binding sites

Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands

Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine

Anticancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation

High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid

Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells

Functional assays to define agonists and antagonists of the sigma-2 receptor

Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes

Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells

Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity

Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity

PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships

Why PB28 Could Be a Covid 2019 Game Changer

MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor

Interaction of the sigma(2) receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer

Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations

Exploring the importance of piperazine Natoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-propyl]piperazine (PB28)

Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity

-fluorophenyl)piperazin-1-yl)butyl)benzo

Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands

Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo

Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands

Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ(2)R/TMEM97 ligands

Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers

High-affinity sigma-1 (σ(1)) receptor ligands based on the σ(1) antagonist PB212

Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracers

Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ 2 receptors

Synthesis and pharmacological evaluation of σ2 receptor ligands based on a 3-alkoxyisoxazole scaffold: potential antitumor effects against osteosarcoma

From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design

Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones

Collateral sensitivity as a strategy against cancer multidrug resistance

Small-Molecule Sigma1Modulator Induces Autophagic Degradation of PD-L1

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms

Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration